These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Substitution therapy of hypogonadal men with transdermal testosterone over one year. Bals-Pratsch M; Langer K; Place VA; Nieschlag E Acta Endocrinol (Copenh); 1988 May; 118(1):7-13. PubMed ID: 3133918 [TBL] [Abstract][Full Text] [Related]
23. Paternity in idiopathic hypothalamic hypogonadism during testosterone therapy in two unrelated patients. de Lange WE; Doorenbos H Neth J Med; 1990 Aug; 37(1-2):77-9. PubMed ID: 2120600 [TBL] [Abstract][Full Text] [Related]
24. Zinc substitution for male dialysis patients: positive effect on preexisting hypogonadism? Schäfer M; Mies R; Vlaho M Contrib Nephrol; 1984; 38():116-8. PubMed ID: 6425012 [No Abstract] [Full Text] [Related]
25. Prolactin-to-Testosterone Ratio Predicts Pituitary Abnormalities in Mildly Hyperprolactinemic Men with Symptoms of Hypogonadism. Naelitz B; Shah A; Nowacki AS; Bryk DJ; Farber N; Parekh N; Shoskes D; Hatipoglu B; Vij SC J Urol; 2021 Mar; 205(3):871-878. PubMed ID: 33080146 [TBL] [Abstract][Full Text] [Related]
26. Effects of gonadotropin and testosterone treatments on Lipoprotein(a), high density lipoprotein particles, and other lipoprotein levels in male hypogonadism. Ozata M; Yildirimkaya M; Bulur M; Yilmaz K; Bolu E; Corakci A; Gundogan MA J Clin Endocrinol Metab; 1996 Sep; 81(9):3372-8. PubMed ID: 8784099 [TBL] [Abstract][Full Text] [Related]
27. Hypogonadism in a male with an immunologically active, biologically inactive luteinizing hormone: characterization of the abnormal hormone. Beitins IZ; Axelrod L; Ostrea T; Little R; Badger TM J Clin Endocrinol Metab; 1981 Jun; 52(6):1143-9. PubMed ID: 6785294 [No Abstract] [Full Text] [Related]
28. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. Matsumoto AM J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626 [TBL] [Abstract][Full Text] [Related]
29. Impaired prolactin response to thyrotropin-releasing hormone in isolated gonadotropin deficiency and exaggerated response in primary testicular failure. Spitz IM; Zylber E; Cohen H; Almaliach U; Leroith D J Clin Endocrinol Metab; 1979 Jun; 48(6):941-5. PubMed ID: 109459 [No Abstract] [Full Text] [Related]
30. Modulation of pulsatile gonadotropin secretion by testosterone in man. Matsumoto AM; Bremner WJ J Clin Endocrinol Metab; 1984 Apr; 58(4):609-14. PubMed ID: 6421864 [TBL] [Abstract][Full Text] [Related]
31. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. Merza Z; Blumsohn A; Mah PM; Meads DM; McKenna SP; Wylie K; Eastell R; Wu F; Ross RJ Int J Androl; 2006 Jun; 29(3):381-91. PubMed ID: 16390499 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study. Meikle AW; Arver S; Dobs AS; Sanders SW; Rajaram L; Mazer NA J Clin Endocrinol Metab; 1996 May; 81(5):1832-40. PubMed ID: 8626843 [TBL] [Abstract][Full Text] [Related]
33. Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men. Stuenkel CA; Dudley RE; Yen SS J Clin Endocrinol Metab; 1991 May; 72(5):1054-9. PubMed ID: 1902483 [TBL] [Abstract][Full Text] [Related]
34. Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment. Ribeiro RS; Abucham J Eur J Endocrinol; 2009 Jul; 161(1):163-9. PubMed ID: 19359408 [TBL] [Abstract][Full Text] [Related]
36. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497 [TBL] [Abstract][Full Text] [Related]
37. Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants. Kelleher S; Conway AJ; Handelsman DJ Clin Endocrinol (Oxf); 2001 Oct; 55(4):531-6. PubMed ID: 11678837 [TBL] [Abstract][Full Text] [Related]
38. Exaggerated prolactin response to thyrotropin-releasing hormone as a function of androgen deficiency. Hetzel WD; Siebling U; Pfeiffer EF Horm Metab Res; 1990 Dec; 22(12):648-9. PubMed ID: 2127583 [No Abstract] [Full Text] [Related]
39. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. Chiang HS; Hwang TI; Hsui YS; Lin YC; Chen HE; Chen GC; Liao CH Int J Impot Res; 2007; 19(4):411-7. PubMed ID: 17538639 [TBL] [Abstract][Full Text] [Related]
40. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. Bhasin S; Swerdloff RS; Steiner B; Peterson MA; Meridores T; Galmirini M; Pandian MR; Goldberg R; Berman N J Clin Endocrinol Metab; 1992 Jan; 74(1):75-83. PubMed ID: 1727832 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]